Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dependence receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Dependence receptor. Displaying page 1 of 1.
    EudraCT Number: 2007-006523-12 Sponsor Protocol Number: 19521952 Start Date*: 2009-08-12
    Sponsor Name:Julio Bobes
    Full Title: Mejora de la efectividad de los tratamientos de mantenimiento con naltrexona en adictos a opiáceos con la adicción de buprenorfina sublingual. Improvement of naltrexone maintenance treatment effec...
    Medical condition: Dependencia de opiáceos. Opiate dependence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004912-30 Sponsor Protocol Number: aprepitant1 Start Date*: 2008-07-31
    Sponsor Name:Karolinska Institutet
    Full Title: Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study
    Medical condition: opiate abuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039004 Reversal of opiate activity LLT
    9.1 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015837-55 Sponsor Protocol Number: RAA09-004 Start Date*: 2010-08-17
    Sponsor Name:Kings College London [...]
    1. Kings College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Double-blind, 36 month, placebo-controlled trial of mifepristone on cognition in alcoholics
    Medical condition: Alcoholism
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10001639 Alcoholism PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005538-59 Sponsor Protocol Number: 22-09-2008 Start Date*: 2009-02-18
    Sponsor Name:ZonMw
    Full Title: Impulsivity, a risk factor in relapse to substance use disorder: investigating neural substrates before and after pharmacological challenges
    Medical condition: Alcohol dependence Cocaine dependence
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003343-11 Sponsor Protocol Number: GLP1ALCOHOL Start Date*: 2017-04-12
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001125 Addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000829-55 Sponsor Protocol Number: PSILO4ALCO Start Date*: 2020-12-16
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.
    Medical condition: Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    21.1 10037175 - Psychiatric disorders 10001590 Alcohol addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003711-51 Sponsor Protocol Number: Otto M. Lesch Start Date*: 2006-12-15
    Sponsor Name:Otto M. Lesch
    Full Title: IBIS- International Baclofen Interventional Study
    Medical condition: Preclinical pharmacological and behavioral data indicate that baclofen, a GABAB receptor agonist, modifies some neurobiological factors contributing to alcohol consumption (Cousins et al., 2001). P...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000550-31 Sponsor Protocol Number: 87,1,2007_01_30 Start Date*: 2007-10-01
    Sponsor Name:IFS gGmbH, Universitätsmedizin Göttingen
    Full Title: Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study
    Medical condition: relapse prevention of alcoholics suffering from persisting craving and/or affective symptoms
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002564-24 Sponsor Protocol Number: B490 Start Date*: 2011-10-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer
    Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003542-17 Sponsor Protocol Number: FISM_IRON-MDS Start Date*: 2019-05-06
    Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS
    Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS
    Medical condition: Adult patients with low risk MDS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000783-14 Sponsor Protocol Number: SY-1425-201 Start Date*: 2017-10-27
    Sponsor Name:Syros Pharmaceuticals Inc.
    Full Title: A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2014-000584-41 Sponsor Protocol Number: BP-004 Start Date*: 2014-10-23
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders
    Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000091-11 Sponsor Protocol Number: PR200-102 Start Date*: 2021-09-21
    Sponsor Name:Prometheus Biosciences, Inc.
    Full Title: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Activ...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:48:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA